LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting (“AGM”), a nomination committee for the 2025 AGM has been appointed.
The nomination committee for the 2025 AGM has been established based on the largest owners as of September 30, 2024, who wish to participate in the nomination committee. The nomination committee has the following composition, which together represent approximately 60 percent of all shares in Spago Nanomedical:
Peter Lindell, represents Cidro Förvaltning AB and own holding, chairman of the Nomination Committee
Mikael Lönn, represents own holding
Eva Redhe, represents own holding
The nomination committee’s task is, among other things, to submit proposals to the AGM for the chairman of the AGM, election of chairman and other members of the board of directors, as well as remuneration to each of the board members. The nomination committee shall also submit proposals for the election and remuneration of auditors.
Shareholders who wish to submit proposals to the nomination committee are welcome to send them by e-mail to valberedning2025@spagonanomedical.se . Proposals shall be submitted no later than January 31, 2025.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.
Attachments
Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2025
SOURCE: Spago Nanomedical
View the original press release on accesswire.com
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…